Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| REVOLUTION MEDICINES | 12 | 5 | -1,62 % | ||
| VENTYX BIOSCIENCES | 11 | - | +0,73 % | ||
| CORMEDIX | 9 | 10 | 0,00 % | ||
| BIONTECH | 7 | 13 | -0,29 % | ||
| INDIVIOR | 5 | 4 | -0,67 % | ||
| ALUMIS | 5 | 2 | 0,00 % | ||
| PACIRA BIOSCIENCES | 5 | 1 | -1,79 % | ||
| KALVISTA PHARMACEUTICALS | 5 | 1 | +1,47 % | ||
| VANDA PHARMACEUTICALS | 5 | - | +1,59 % | ||
| ARDELYX | 4 | 8 | -0,27 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:26 | Mesoblast Ryoncil Sales Surge 60% in December Quarter | 1 | Finance News Network | ||
| 03:35 | Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today | 7 | The Motley Fool Australia | ||
| 01:26 | Mesoblast Sales Surge 60% in December Quarter, Bolstered by New Financing | 1 | Finance News Network | ||
| 01:05 | Why are Mesoblast shares jumping 10% to a 52-week high? | 1 | The Motley Fool Australia | ||
| 00:54 | Mesoblast Limited: Ryoncil Sales Increase 60% in December Quarter to US$35.1M | 1 | GlobeNewswire (USA) | ||
| 00:18 | AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute | 4 | Investing.com | ||
| 00:06 | AnaptysBio, Inc.: Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | 2 | GlobeNewswire (USA) | ||
| 00:01 | Pacira drops after adjusting 2025 revenue below consensus | 2 | Seeking Alpha | ||
| Do | MESOBLAST LIMITED: Ryoncil Sales for the Quarter Increase 60% to US$35.1M | - | ASX | ||
| Do | Praxis Precision Medicines appoints new board members, promotes executives | 1 | Investing.com | ||
| Do | Presse: US-Pharmakonzern Merck vor Milliardenkauf von Revolution Medicines | 9 | cash | ||
| Do | 'FT': US-Pharmakonzern Merck vor Milliardenkauf von Revolution Medicines | 739 | dpa-AFX | LONDON (dpa-AFX) - Der US-Pharmakonzern Merck & Co will einem Zeitungsbericht zufolge den Krebsmittelspezialisten Revolution Medicines übernehmen. Als Kaufpreis seien 28 bis 32 Milliarden US-Dollar... ► Artikel lesen | |
| Do | KalVista: Starke Umsatzzahlen für HAE-Medikament EKTERLY treiben Aktie an | - | Investing.com Deutsch | ||
| Do | Grabar Law Office: Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement | 229 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation... ► Artikel lesen | |
| Do | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | 1 | GlobeNewswire (USA) | ||
| Do | Merck in talks to buy biotech Revolution Medicines, FT reports | 13 | Reuters | ||
| Do | Thomas Riga wird neuer Chief Business Officer bei Jazz Pharmaceuticals | 3 | Investing.com Deutsch | ||
| Do | KalVista meldet 35 Mio. USD Quartalsumsatz mit HAE-Medikament EKTERLY | 1 | Investing.com Deutsch | ||
| Do | Neue Gerüchte! Merck & Co wirft Auge auf AKTIONÄR-Tipp Revolution Medicines | 584 | Der Aktionär | Der US-Pharmariese Merck & Co bereitet offenbar den nächsten großen Coup vor. Laut Insidern befindet sich der Konzern in fortgeschrittenen Gesprächen über den Kauf des Krebsspezialisten Revolution Medicines.... ► Artikel lesen | |
| Do | Pacira reports preliminary FY25 revenue of $726.4M | 2 | Seeking Alpha |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .